-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on AnaptysBio, Raises Price Target to $75

Benzinga·05/13/2026 14:09:35
Listen to the news
Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $63 to $75.